Unveiling the Science Behind Our Innovative Particles

NanoMedTrix develops novel multi-modal, targeted contrast agents MSNs for use across a range of disciplines, including regenerative technology and targeted radiology in medical imaging. Contrast agents are used to enhance the visibility of structures or fluids in the body during scans, such as MRI, CT and ultrasound.

https://nanomedtrix.com/wp-content/uploads/2023/05/nanovideo.mp4

In the animation, a mouse bladder (blue, 5 mm in size) is rendered 3 dimensionally with the help of MSN, highlighting a very large and invasive tumor (red).

Revolutionize Your Trials with Faster, More Accurate Results and Lower Costs

Our products are based on nanoparticle technology, which allows us to create products that are simple and easy-to-use, combining fluorescence, magnetic resonance imaging (MRI) and/or computed tomography (CT) with ultrasound imaging signaling capability. This allows for visual seamless validation from in vitro specimens to transplants in vivo.


Improve Your Trials

In Applications

Our products have been used in a variety of biomedical applications. We are committed to providing our products to physicians for clinical applications. We believe that our products have the potential to improve the diagnosis and treatment of a variety of diseases.

Cancer

Our products have been used to target solid tumors, such as bladder, colorectal, and neural tumors.

Preclinical Studies

Our products have been used in preclinical studies to assess the safety and efficacy of new drugs and treatments.

Clinical Studies

Our products are currently being evaluated in clinical studies to assess their safety and efficacy in humans.

Ready to Revolutionize
Nanotechnology?

Reach out and learn how advanced nanoparticles can help you achieve superior imaging diagnostics and targeted drug delivery. 


Contact Now

Peer-reviewed Publications

Click on the article to access

Sweeney, S. K.; Luo, Y.; O’Donnell, M. A.; Assouline, J. Nanotechnology and cancer: improving real-time monitoring and staging of bladder cancer with multimodal mesoporous silica nanoparticles. Cancer. Nanotechnol 2016, 7, 3.

Sweeney, S. K.; Adamcakova-Dodd, A.; Thorne, P. S.; Assouline, J. Biocompatibility of multi-imaging engineered mesoporous silica nanoparticles: in vitro and adult and fetal in vivo studies. J Biomed Nanotech 2017, 13, 544-558.

Sweeney, S. K.; Luo, Y.; O’donnell, M. A.; Assouline, J. Peptide-mediated targeting mesoporous silica nanoparticles: a novel tool for fighting bladder cancer. J Biomed Nanotech 2017, 13, 232-242.

Sweeney, S.; Adamcakova-Dodd, A.; Thorne, P. S.; Assouline, J. G. Multifunctional nanoparticles for real-time evaluation of toxicity during fetal development. PLoS One 2018, 13, e0192474.

Sweeney, S. K.; Manzar, G. S.; Zavazava, N.; Assouline, J. G. Tracking embryonic hematopoietic stem cells to the bone marrow: nanoparticle options to evaluate transplantation efficiency. Stem Cell. Res. Ther. 2018, 9, 204-018-0944-8.

Affiliations